OncoMed Makes Board Appointment
This article was originally published in Scrip
OncoMed Pharmaceuticals, Inc. has appointed recently retired CEO of Celgene Cellular Therapeutics, Perry Karsen, to its board of directors. Previously, Karsen was executive vice president and chief operations officer at Celgene Corporation and also served as senior vice president and head of worldwide business development at the company. He has also been CEO of Pearl Therapeutics and held executive positions at Human Genome Sciences, Bristol-Myers Squibb, Genentech and Abbott Laboratories earlier in his career.
You may also be interested in...
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.